Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment
Dr. Wesley Burks of the University of North Carolina will present study data
BRISBANE, Calif., June 3, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the topline results from its Phase 2 study evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 in Barcelona.
Dr. Wesley Burks, chairman of the department of pediatrics at the University of North Carolina School of Medicine and physician in chief of N.C. Children’s Hospital at the University of North Carolina School of Medicine, will present the data in a late-breaking oral abstract session.
|Title:||A novel characterized peanut allergen formulation (AR101) for oral immunotherapy (OIT) induces desensitization in peanut-allergic subjects: A Phase 2 clinical safety and efficacy study (Abstract 2378)|
|Presenter:||Wesley Burks, M.D.|
|Date:||Sunday, June 7, 2015|
|Time:||3:53 p.m. — 4:06 p.m. Central European Time|
|Session:||Food Allergy and Omics, 3:30 p.m. — 5 p.m. Central European Time|
About Food Allergies
Food allergies are a significant and growing health problem in the United States, Europe and throughout the developed world. It is estimated that more than 30 million people in the United States and Europe have a food allergy. Specifically, the prevalence of peanut allergy in children in the United States is estimated to have increased at a constant annual growth rate of 10 percent between 1997 and 2008, and experts believe it has continued to rise. For people living with food allergies, certain foods can cause severe allergic reactions, including potentially life-threatening anaphylaxis. There is no cure for food allergies. Currently, food-allergic patients manage their condition by strict allergen avoidance and carrying epinephrine auto-injectors for use in case of accidental exposure. Thus, in addition to the unmet medical need, food allergies can impose a significant quality of life burden. For more information, please see www.foodallergy.org and www.niaid.nih.gov/topics/foodallergy.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Aimmune Therapeutics’ characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens. Aimmune Therapeutics recently completed a Phase 2 study of its lead product, AR101, a standardized, complex mixture of naturally occurring proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies. Aimmune Therapeutics is also developing products for other common food allergies for use with the CODIT system. For more information, please see www.aimmune.com.
# # #